← All trials
NCT03622788
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2018
- Primary completion
- Apr 1, 2020
- Completion date
- Apr 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
- Bone Marrow Failure Disorders
- Anemia, Aplastic
- Hodgkin Disease
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Lymphoma, Mantle-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.